Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Forst

Showing results (51-60 of 148) with videos related to

Pageof 15
Sort By:
Journal of Diabetes Science and Technology|September 2, 2011
Analysis of the environmental impact of insulin infusion sets based on loss of resources with wasteAndreas Pfützner, Petra B Musholt, Bjoern Malmgren-Hansen, et al.
Clinical Laboratory|November 10, 2009
Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat studyAndreas Pfützner, Karagiannis Efstrathios, Mirjam Löbig, et al.
Diabetes Technology & Therapeutics|June 1, 2006
Evaluation of CGMS during rapid blood glucose changes in patients with type 1 diabetesBirgit Wilhelm, Senait Forst, Matthias M Weber, et al.
Diabetes Care|June 19, 2007
Development and validation of a new measure to evaluate psychological resistance to insulin treatmentFrank Petrak, Elmar Stridde, Friedhelm Leverkus, et al.
Journal of Diabetes Science and Technology|November 6, 2009
Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndromeCharles A Steiner, Andrej Janez, Mojca Jensterle, et al.
Diabetes, Obesity & Metabolism|October 7, 2024
A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesityNadine Beetz, Brigitte Kalsch, Thomas Forst, et al.
Diabetes Technology & Therapeutics|January 5, 2005
Evaluation of SET--a new device for the measurement of pain perception in comparison to standard measures of diabetic neuropathyMai Nguyen, Wolfgang Henniges, Michael Lobisch, et al.
Diabetes Care|May 29, 2002
Effect of C-peptide on glucose metabolism in patients with type 1 diabetesThomas Forst, Klaus Rave, Andreas Pfuetzner, et al.
Diabetology & Metabolic Syndrome|September 6, 2013
Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabeticsStefan Pscherer, Thomas Freude, Thomas Forst, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 23, 2024
Diabetes Mellitus and the HeartKatharina Schütt, Thomas Forst, Andreas L Birkenfeld, et al.
Pageof 15

Showing results (51-60 of 148) with videos related to

Sort By:
Pageof 15
Journal of Diabetes Science and Technology|September 2, 2011
Analysis of the environmental impact of insulin infusion sets based on loss of resources with wasteAndreas Pfützner, Petra B Musholt, Bjoern Malmgren-Hansen, et al.
Clinical Laboratory|November 10, 2009
Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat studyAndreas Pfützner, Karagiannis Efstrathios, Mirjam Löbig, et al.
Diabetes Technology & Therapeutics|June 1, 2006
Evaluation of CGMS during rapid blood glucose changes in patients with type 1 diabetesBirgit Wilhelm, Senait Forst, Matthias M Weber, et al.
Diabetes Care|June 19, 2007
Development and validation of a new measure to evaluate psychological resistance to insulin treatmentFrank Petrak, Elmar Stridde, Friedhelm Leverkus, et al.
Journal of Diabetes Science and Technology|November 6, 2009
Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndromeCharles A Steiner, Andrej Janez, Mojca Jensterle, et al.
Diabetes, Obesity & Metabolism|October 7, 2024
A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesityNadine Beetz, Brigitte Kalsch, Thomas Forst, et al.
Diabetes Technology & Therapeutics|January 5, 2005
Evaluation of SET--a new device for the measurement of pain perception in comparison to standard measures of diabetic neuropathyMai Nguyen, Wolfgang Henniges, Michael Lobisch, et al.
Diabetes Care|May 29, 2002
Effect of C-peptide on glucose metabolism in patients with type 1 diabetesThomas Forst, Klaus Rave, Andreas Pfuetzner, et al.
Diabetology & Metabolic Syndrome|September 6, 2013
Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabeticsStefan Pscherer, Thomas Freude, Thomas Forst, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 23, 2024
Diabetes Mellitus and the HeartKatharina Schütt, Thomas Forst, Andreas L Birkenfeld, et al.
Pageof 15